drugset / Trial / NCT00098865
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Phase 2
Completed
15 enrolled
Dana-Farber Cancer Institute
Boston Children's Hospital · collabCelgene Corporation · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with temozolomide may kill more tumor cells. PURPOSE: This phase II trial is studying the effectiveness of combining thalidomide with temozolomide in treating young patients who have relapsed or progressive brain tumors or recurrent neuroblastoma.
Timeline
- Start
- 2002-09
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |
| Subject | Thalidomide | Other / unclassified | 24 mg/kg | Oral |
| Subject | Thalidomide | Other / unclassified | 1000 mg | Oral |